Huaxin Medical Completes Hundreds of Millions RMB Series A+ Strategic Financing Led by Yuwell Medical and Shengyu Investment, with WinX Capital as Exclusive Financial Advisor

VCBeat (WeChat: vcbeat) learned at the earliest opportunity thatRecently, Hunan Huaxin Medical Device Co., Ltd. (“Huaxin Medical”) announced the completion of its A+ round strategic financing, amounting to hundreds of millions of yuan, with joint investment from Yuwell Medical and Sharewin Investment. WinX Capital served as the exclusive financial advisor for the third consecutive time.

As an industrial investor, Yuwell Medical will not only provide financial support to Huaxin Medical but also empower its development through industrial resources and operational management expertise. Following this round of financing, Huaxin Medical will further expand production capacity and accelerate the global layout of its sales channels. The company will continue to enrich its product pipeline, with multiple blockbuster products scheduled for global launch within the next six months.

Huaxin Medical is the global leader in single-use endoscopes. Olympus serves as Huaxin Medical’s exclusive general distributor in the United States, and the company also collaborates with other world-renowned corporations such as Boston Scientific and TKB. Its products have entered the markets of dozens of developed countries worldwide, securing explosive order growth.

The company’s single-use electronic bronchoscope holds regulatory approvals from the FDA, CE, NMPA, as well as in Japan, South Korea, and other countries/regions worldwide. In October 2021, it received China’s first registration certificate for this product, signaling that Huaxin’s products are poised to enter the domestic market and create a new growth engine. On March 1, 2022, the company’s independently developed “Medical Endoscope Image Processor” was approved for marketing in the United States, significantly solidifying Huaxin Medical’s position as a global leader in single-use endoscopes and marking a milestone victory in its global market expansion.

Validated by the international market, Huaxin Medical’s disposable electronic bronchoscope system has achieved technical and economic indicators on par with advanced international counterparts, underscoring its strong product competitiveness. Amid the recurring waves of the COVID-19 pandemic, the advantages of disposable electronic bronchoscopes—namely, the ability to prevent cross-infection, low procurement costs, and simple operational procedures—have become increasingly prominent, making them a key product in the fight against COVID-19.

Looking ahead, the replacement of reusable endoscopes by single-use endoscopes has become an inevitable trend. In certain application scenarios, single-use endoscopes are an essential necessity. The global endoscope market is projected to reach hundreds of billions of yuan in China and trillions of yuan worldwide by 2025. During this period, single-use endoscopes are bound to occupy an increasingly larger share of the market.

Huaxin Medical has remained dedicated to the research, development, production, and sales of disposable electronic endoscopes. Its comprehensive product portfolio spans respiratory, gastrointestinal, proctology, and orthopedic specialties. The company boasts a robust closed-loop system integrating R&D, product development, and marketing and sales. Leveraging breakthroughs in core technologies, Huaxin Medical delivers global premium quality while achieving low-cost, consumable-based solutions. This enables specialized product integration and iterative innovation, positioning the company to lead the technological transformation in endoscopy.

For this round of financing,The founder of Huaxin Medical stated:Thanks to the strategic investments from Yuwell Medical and Sharewin Investment, Huaxin Medical remains committed to enhancing its independent R&D capabilities in key technologies and front-end components, as well as its end-to-end manufacturing capabilities. Meanwhile, it is taking a global lead in building sales channels and will launch a series of blockbuster products with innovative and differentiated competitiveness in the future.

Sharewin Investment stated:Sharewin Investment has always focused on platform-based projects with core technologies, deploying department-specific solutions centered around clinical benefits. As a leading domestic platform enterprise in the field of single-use endoscopes, Huaxin’s products cover scenarios such as ICUs, point-of-care diagnostics and treatment, and ambulatory surgery, thereby improving the accessibility of endoscopy in primary healthcare institutions. Sharewin Investment is optimistic about the sector in which Huaxin operates. As a strategic investor, Sharewin is committed to supporting the company’s long-term development and growth, helping Huaxin become an internationally leading single-use endoscopy platform company.

Yuwell Medical stated:Yuwell Medical has always adhered to its mission of “alleviating patients’ suffering and empowering physicians to enhance their clinical expertise,” actively promoting the establishment of an ecosystem of medical technologies and devices that benefit human health. As a technological pioneer in China’s disposable endoscopy field, Huaxin Medical drives and expands the application of this technology into new scenarios for specialized examination and treatment in respiratory, urological, and gastrointestinal disciplines. Yuwell is honored to collaborate with Huaxin in the future to jointly advance the deployment of next-generation endoscopic technology across diverse medical settings, thereby contributing to the development of China’s medical industry.

Dr. Zou Guowen, Founder of WinX Capital, stated:Huaxin Medical is the global leader in single-use endoscopes, endorsed by top-tier manufacturers worldwide such as Olympus. It has entered dozens of developed markets, including Europe, the United States, and Japan, securing explosive order growth. Global expansion capability is a key indicator of a company’s competitive advantage, and we are honored to serve as Huaxin Medical’s long-term capital partner.

Hunan Huaxin Medical Device Co., Ltd. was established in 2018, with its headquarters located in the Jiuhua Economic and Technological Development Zone, Xiangtan City, Hunan Province (Hunan Medical Device Industrial Park). The company specializes in the research and development, production, and sales of disposable endoscopes. Its product portfolio primarily consists of sterile endoscopes for departments including pulmonology, gastroenterology, proctology, and orthopedics, and the company has obtained dozens of patent certifications. The company’s disposable bronchoscopes have received registration clearance from the U.S. FDA, European CE marking, as well as regulatory approvals in Japan, South Korea, and other countries, along with ISO 13485 quality management system certification. Over the years, the company has remained committed to the medical pursuit of “striving for perfection,” adhering to the corporate philosophy of “integrity as the foundation, innovation for long-term success.” It is dedicated to pursuing, developing, and manufacturing higher-quality disposable endoscopic medical devices, making healthcare more accessible.

A China A-share listed company established in 1998. As one of the largest medical device suppliers in China, it serves over 300,000 healthcare institutions domestically and more than 90% of Grade III Class A hospitals, with a presence in over 110 countries and regions worldwide, benefiting 300 million households globally. Building on its cornerstone businesses in blood pressure monitoring, temperature monitoring, traditional Chinese medicine equipment, and surgical instruments, the company’s product strategy focuses on three core sectors: respiratory care, diabetes management, and infection control, while incubating three emerging sectors: emergency care, ophthalmology, and intelligent rehabilitation.

Since 2011, Sharewin Medical’s investment team has focused its strategic layout in the broader healthcare industry on IVD and biopharmaceuticals, medical devices and consumables, and smart healthcare, guided by the strategies of “specialization” and “industry partnership.” In the smart healthcare sector, Sharewin has invested in a number of technology-driven leading companies in niche markets, fostering product and channel synergies within the Sharewin medical ecosystem.

WinX Capital is a leading investment bank in China’s healthcare and wellness sector. Five members of its founding team hold Ph.D.s in Global Finance from the PBC School of Finance at Tsinghua University, while its frontline team boasts an average of over 10 years of experience in management, investment, and M&A, with cumulative transaction values exceeding RMB 30 billion. Headquartered in Beijing and Shanghai, WinX Capital covers more than 3,000 active institutional investors and industrial groups. In 2020 and 2021, it was consecutively ranked among the “Top 5 Most Promising Emerging Investment Banks in China” by 36Kr (WISE 2020/2021); listed as one of the “Top 4 Most Active Financial Advisors in Healthcare and Medicine for 2021” by First New Voice; and recognized as one of the “Top 4 Best Financial Advisory Firms in Healthcare and Medicine for 2020” and “Top 2 Best Financial Advisory Firms in Healthcare and Medicine for 2021” by Qiming Technology & Xinsheng Chuangfu.